Table 1 Characteristics of 249 chronic HBV-infected patients treated with pegylated interferon α-2a or nucleos(t)ide analogues

Patients (n)

72

58

53

39

27

Age (year)

28.69 ± 8.09

30.29 ± 8.55

28.62 ± 8.73

27.33 ± 6.47

30.11 ± 9.81

0.579^a

Male sex [n (%)]

59(81.94%)

48(82.76%)

35(66.04%)

31(79.49%)

22(81.48%)

0.904^b

HBV DNA (log10 copies/ml)

7.40 ± 0.94

7.58 ± 1.53

7.87 ± 1.32

8.17 ± 1.37

<2

0.019^a

ALT (U/L)

172.5 ± 173.6

131.9 ± 128.6

176.1 ± 145.7

162.6 ± 92.12

31.32 ± 26.32

<0.0001^c

AST (U/L)

95.44 ± 72.68

97.69 ± 152.4

122.7 ± 133.8

98.10 ± 55.33

29.25 ± 10.92

<0.0001^c

BUN (mmol/L)

4.45 ± 0.98

4.37 ± 1.10

4.68 ± 1.27

4.87 ± 1.16

5.16 ± 1.34

0.025^a

Cr (mg/dl)

0.93 ± 0.11

0.75 ± 0.12

0.74 ± 0.13

0.75 ± 0.11

0.77 ± 0.13

<0.0001^a

CKD-EPI eGFR (mL/min/1.73 m²)

106.3 ± 13.99

121.2 ± 10.38

121.5 ± 11.21

123.1 ± 9.64

120.1 ± 11.50

<0.0001^a

MDRD eGFR (mL/min/1.73 m²)

100.00 ± 14.68

127.7 ± 22.13

126.4 ± 20.96

127.4 ± 20.16

125.1 ± 22.69

<0.0001^a